Saturday 17 October 2026
Export OMER’s income statement to Excel — free account
Omeros Corporation
OMER Healthcare Biotechnology
In the quarter to June 2026, revenue grew 35.5%, EPS grew 141.9%, free cash flow grew 118.7% and total debt fell 42.0%, each against the same quarter a year earlier.
16.20
2.59
−13.78%
Follow OMER
Omeros Corporation (OMER) P/E ratio
As of 16 October 2026, Omeros Corporation (OMER) trades at a P/E ratio of 9.5×. Over the past ten years it has ranged from 0.0× (March 2026) to 13.7× (May 2026); the current reading is higher than 96% of that period. That is above the Biotechnology industry median of 8.5× and below the Healthcare sector median of 23.0×.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2020 | 0.0× | — |
| FY2019 | 0.0× | — |
| FY2018 | 0.0× | — |
| FY2017 | 0.0× | — |
| FY2016 | 0.0× | — |
| FY2015 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Jun 2026 | 5.6× | (42.07%) |
| Mar 2026 | 9.6× | — |
| Sep 2021 | 0.0× | — |
| Jun 2021 | 0.0× | — |
| 25 more quarters | Free account |
Against its own ten years
Low 0.0×
High 13.7×
Ten-year median
0.0×
Current reading's percentile
96
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| GHRS GH Research PLC compare | n/m |
| TYRA Tyra Biosciences, Inc. compare | n/m |
| ANAB AnaptysBio, Inc. compare | n/m |
| NKTR Nektar Therapeutics compare | n/m |
| ORIC Oric Pharmaceuticals, Inc. compare | n/m |
| INBX Inhibrx Biosciences, Inc. compare | n/m |
| RAPP Rapport Therapeutics, Inc. compare | n/m |
| OMER Omeros Corporation | 9.5× |
| AAPG Ascentage Pharma Group International - Unsponsored ADR compare | — |
| Biotechnology industry median | 8.5× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)